Monitoring immune-checkpoint blockade: Response evaluation and biomarker development

Nature Reviews Clinical Oncology

Volumn 14, Issue 11, 2017, Pages 655-668

  Nishino, Mizuki ^a   Ramaiya, Nikhil H ^a   Hatabu, Hiroto ^a   Hodi, F Stephen ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; GAMMA INTERFERON; IMMUNE CHECKPOINT BLOCKADE; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; REVIEW; SERUM; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DISEASE COURSE; GENETICS; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 85029354547     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2017.88     Document Type: Review

References (91)

1. Lenschow, D. J., Walunas, T. L. & Bluestone, J. A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233-258 (1996).
2. Ott, P. A., Hodi, F. S. & Robert, C. CTLA-4 and PD-1/ PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer Res. 19, 5300-5309 (2013).
3. Nishino, M. et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am. J. Roentgenol. 198, 737-745 (2012).
4. Nishino, M., Tirumani, S. H., Ramaiya, N. H. & Hodi, F. S. Cancer immunotherapy and immune-related response assessment: the role of radiologists in the new arena of cancer treatment. Eur. J. Radiol. 84, 1259-1268 (2015).
5. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
6. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
7. Nishino, M., Gargano, M., Suda, M., Ramaiya, N. H. & Hodi, F. S. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J. Immunother. Cancer 2, 17 (2014).
8. Nishino, M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin. Cancer Res. 19, 3936-3943 (2013).
9. Nishino, M. et al. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J. Immunother. Cancer 4, 84 (2016).
10. Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
11. Miller, A. B., Hoogstraten, B., Staquet, M. & Winkler, A. Reporting results of cancer treatment. Cancer 47, 207-214 (1981).
12. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205-216 (2000).
13. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
14. Lynch, T. J. et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30, 2046-2054 (2012).
15. Hodi, F. S. et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J. Clin. Oncol. 34, 1510-1517 (2016).
16. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
17. Nishino, M., Jagannathan, J. P., Ramaiya, N. H. & Van den Abbeele, A. D. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am. J. Roentgenol. 195, 281-289 (2010).
18. Chiou, V. L. & Burotto, M. Pseudoprogression and immune-related response in solid tumors. J. Clin. Oncol. 33, 3541-3543 (2015).
19. Nishino, M., Hatabu, H., Johnson, B. E. & McLoud, T. C. State of the art: response assessment in lung cancer in the era of genomic medicine. Radiology 271, 6-27 (2014).
20. Nishino, M. Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment. J. Immunother. Cancer 4, 30 (2016).
21. Erasmus, J. J. et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J. Clin. Oncol. 21, 2574-2582 (2003).
22. Nishino, M. et al. CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of an emerging clinical tool. Acad. Radiol. 18, 54-62 (2011).
23. Oxnard, G. R. et al. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J. Clin. Oncol. 29, 3114-3119 (2011).
24. Zhao, B. et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology 252, 263-272 (2009).
25. Nishino, M. et al. Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-17-0114 (2017).
26. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330 (2015).
27. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532 (2015).
28. Okada, H. et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 16, e534-e542 (2015).
29. Gettinger, S. N. et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 33, 2004-2012 (2015).
30. Bohnsack, O., Hoos, A. & Ludajic, K. Adaptation of the immune-related response criteria: irRECIST [abstract 1070P]. Ann. Oncol. 25, iv369 (2014).
31. Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143-e152 (2017).
32. [No authors listed.] iRECIST. RECIST http://www.eortc. org/recist/irecist/ (2017).
33. Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540-1550 (2016).
34. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
35. Rizvi, N. A. et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16, 257-265 (2015).
36. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
37. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627-1639 (2015).
38. Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909-1920 (2016).
39. McDermott, D. F. et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J. Clin. Oncol. 34, 833-842 (2016).
40. Motzer, R. J. et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J. Clin. Oncol. 33, 1430-1437 (2015).
41. Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803-1813 (2015).
42. McDermott, D. F. et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J. Clin. Oncol. 33, 2013-2020 (2015).
43. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
44. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123-135 (2015).
45. Daud, A. I. et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J. Clin. Oncol. 34, 4102-4109 (2016).
46. Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823-1833 (2016).
47. U.S. Food and Drug Administration. Pembrolizumab (KEYTRUDA) checkpoint inhibitor. FDA https://www. fda.gov/drugs/informationondrugs/approveddrugs/ ucm526430.htm (2016).
48. Hansen, A. R. & Siu, L. L. PD-L1 testing in cancer: challenges in companion diagnostic development. JAMA Oncol. 2, 15-16 (2016).
49. Sacher, A. G. & Gandhi, L. Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol. 2, 1217-1222 (2016).
50. Mahoney, K. M. et al. PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells. Cancer Immunol. Res. 3, 1308-1315 (2015).
51. McLaughlin, J. et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2, 46-54 (2016).
52. Hirsch, F. R. et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC Assay Comparison Project. J. Thorac. Oncol. 12, 208-222 (2017).
53. Mandal, R. & Chan, T. A. Personalized oncology meets immunology: the path toward precision immunotherapy. Cancer Discov. 6, 703-713 (2016).
54. Galon, J. et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J. Pathol. 232, 199-209 (2014).
55. Remon, J., Chaput, N. & Planchard, D. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer. Curr. Opin. Oncol. 28, 122-129 (2016).
56. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
57. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
58. Daud, A. I. et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Invest. 126, 3447-3452 (2016).
59. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
60. Galon, J. et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J. Transl Med. 14, 273 (2016).
61. Bindea, G., Mlecnik, B., Angell, H. K. & Galon, J. The immune landscape of human tumors: implications for cancer immunotherapy. Oncoimmunology 3, e27456 (2014).
62. Pages, F. et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 27, 5944-5951 (2009).
63. Mlecnik, B. et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 29, 610-618 (2011).
64. Ascierto, P. A. et al. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J. Transl Med. 11, 54 (2013).
65. Paulsen, E. E. et al. Assessing PDL-1 and PD-1 in non-small cell lung cancer: a novel immunoscore approach. Clin. Lung Cancer 18, 220-233.e8 (2017).
66. Shukuya, T. & Carbone, D. P. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer. J. Thorac. Oncol. 11, 976-988 (2016).
67. Taube, J. M. et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl Med. 4, 127ra37 (2012).
68. Higgs, B. W. et al. High tumoral IFNg mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients [abstract]. European Cancer Congress (2015).
69. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819-829 (2016).
70. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014).
71. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015).
72. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015).
73. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
74. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
75. Nathanson, T. et al. Somatic mutations and neoepitope homology in melanomas treated with CTLA-4 blockade. Cancer Immunol. Res. 5, 84-91 (2017).
76. Martens, A. et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin. Cancer Res. 22, 2908-2918 (2016).
77. Delyon, J. et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann. Oncol. 24, 1697-1703 (2013).
78. Kelderman, S. et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol. Immunother. 63, 449-458 (2014).
79. Gebhardt, C. et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin. Cancer Res. 21, 5453-5459 (2015).
80. Ku, G. Y. et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116, 1767-1775 (2010).
81. Tietze, J. K. et al. The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. Eur. J. Cancer 75, 268-279 (2017).
82. Diem, S. et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br. J. Cancer 114, 256-261 (2016).
83. Weide, B. et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin. Cancer Res. 22, 5487-5496 (2016).
84. Nishino, M. et al. Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J. Thorac. Oncol. 8, 1059-1068 (2013).
85. Nishino, M. et al. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer 119, 3761-3768 (2013).
86. Nishino, M. et al. Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib. Acad. Radiol. 23, 329-336 (2016).
87. Tavare, R. et al. An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Res. 76, 73-82 (2016).
88. Maute, R. L. et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno- PET imaging. Proc. Natl Acad. Sci. USA 112, E6506-E6514 (2015).
89. National Institutes of Health. New drug formulary will help expedite use of agents in clinical trials. NIH https://www.nih.gov/news-events/news-releases/new-drug-formulary-will-help-expedite-use-agents-clinical-trials (2017).
90. Department of Health and Human Services. Cancer Immune Monitoring and Analysis Centers (CIMACs). NIH https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-005.html (2017).
91. Department of Health and Human Services. Cancer Immunologic Data Commons (CIDC). NIH https:// grants.nih.gov/grants/guide/rfa-files/RFA-CA-17-006. html (2017).